Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.MedImmune has licensed worldwide rights from GlaxoSmithKline to develop certain monoclonal antibodies to combat the staphylococcus class of bacteria.
Subscribe to our email newsletter
The deal includes BSYX-A110, which is in phase II clinical development for the prevention of serious bloodstream infections caused by staphylococcus in low-birthweight infants.
MedImmune will be responsible for future R&D of BSYX-A110 as well as all future sales and marketing activities worldwide.
Under the terms of the agreement, MedImmune will pay GSK an upfront payment upon signing as well as potential milestone payments and royalties on future marketed products. MedImmune has also assumed responsibility for future milestone and royalty payment obligations to Biosynexus, from which GSK originally licensed the BSYX-A110 antibody and related rights in 2002. Biosynexus may continue to provide scientific input regarding future R&D activities for the program.
“Adding BSYX-A110 into the pipeline provides an opportunity for us to leverage MedImmune’s clinical, regulatory and commercial experience in the development of monoclonal antibodies in pediatrics,” said Dr Edward Connor, executive vice president and chief medical officer.
According to the US Census Bureau, approximately 43,000 infants weighing less than 1,250 grams at birth were born in 2001. These low- birthweight infants are particularly susceptible to hospital-acquired infections, such as those caused by staphylococcus.